Cannabinoid Encyclopedia

Health and effects

Cannabinoids and Skin and inflammatory dermatology

What studies can tell us about cannabinoids and Skin and inflammatory dermatology, including human research, early evidence, and important limits.

Updated July 2026 41 research sources Human and early research

The short answer

What does the research say about Skin and inflammatory dermatology?

Researchers have studied cannabinoids in connection with Skin and inflammatory dermatology. The current literature covers CBG, CBN, and CBC. This page brings together 14 human-study sources, 7 research reviews, and 14 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Skin and inflammatory dermatology.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Skin and inflammatory dermatology covers CBG, CBN, and CBC; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Skin and inflammatory dermatology

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human and early-stage research

CBG

Researchers have studied CBG in connection with Skin and inflammatory dermatology. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 2

Mostly mechanism-focused

CBN

Researchers have studied CBN in connection with Skin and inflammatory dermatology. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3

Human and early-stage research

CBC

Researchers have studied CBC in connection with Skin and inflammatory dermatology. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 4

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

14 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

7 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

14 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 41 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on Skin and inflammatory dermatology is not one kind of study. This source set includes 16 cell or laboratory studies, 9 animal studies, 7 narrative or expert reviews, and 1 clinical study in people. 3

The recorded populations or models include people or patients (15 sources), cells or tissue models (9 sources), and animal models (7 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is skin, dermatology, antimicrobial, or topical inflammatory outcomes (21 sources), skin, dermatology, or topical inflammatory outcomes (14 sources), and skin, dermatology, inflammatory, or immune-modulation outcomes (9 sources). Closely related outcome names can still describe different measurements. 5

The Skin and inflammatory dermatology source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus.

On this page, this source examines CBC and skin and inflammatory dermatology. 1

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
skin, dermatology, antimicrobial, or topical inflammatory outcomes
Evidence stage
evidence still limited

cell or laboratory study

Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.

On this page, this source examines CBG and skin and inflammatory dermatology. 2

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
skin, dermatology, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

animal study

Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.

On this page, this source examines CBN and skin and inflammatory dermatology. 3

Study type
animal study
Population or model
people or patients
Outcome focus
skin, dermatology, inflammatory, or immune-modulation outcomes
Evidence stage
mechanism-focused research

cell or laboratory study

Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.

On this page, this source examines CBC and skin and inflammatory dermatology. 4

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
skin, dermatology, antimicrobial, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

human research

Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.

On this page, this source examines CBC and skin and inflammatory dermatology. 5

Population or model
people or patients
Outcome focus
skin, dermatology, antimicrobial, or topical inflammatory outcomes
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on Skin and inflammatory dermatology should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Can cannabinoids help with Skin and inflammatory dermatology?

Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 7

Why can studies reach different answers?

Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 8

What should I check in a study?

Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus. narrative or expert review; evidence still limited PubMed 39596719 DOI 10.3390/antibiotics13111023
  2. 2
    Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research PubMed 39596290 DOI 10.3390/ijms252212224
  3. 3
    Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research PubMed 41680865 DOI 10.1186/s42238-025-00384-7
  4. 4
    Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. cell or laboratory study; mechanism-focused research PubMed 42163693 DOI 10.2174/0109298673390667251201115054
  5. 5
    Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. human research PubMed 41983582 DOI 10.1093/jambio/lxag092
  6. 6
    Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. human research PubMed 40124934 DOI 10.2147/ccid.s472746
  7. 7
    In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. clinical study in people; mechanism-focused research PubMed 35056807 DOI 10.3390/molecules27020491
  8. 8
    Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited PubMed 27435265 DOI 10.1096/fj.201600646r
  9. 9
    Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. narrative or expert review; evidence still limited PubMed 39457041 DOI 10.3390/ijms252011258
  10. 10
    Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. narrative or expert review; evidence still limited PubMed 38673788 DOI 10.3390/ijms25084204
  11. 11
    Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. narrative or expert review; evidence still limited PubMed 37514074 DOI 10.3390/pharmaceutics15071889
  12. 12
    The Potential of Cannabichromene (CBC) as a Therapeutic Agent. narrative or expert review; evidence still limited PubMed 38777605 DOI 10.1124/jpet.124.002166
See all 41 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research / 1 linked research note PubMed 41680865
  2. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37764262
  3. Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39275884
  4. Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36228902
  5. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. narrative or expert review; evidence still limited / 1 linked research note PubMed 38673788
  6. Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited / 1 linked research note PubMed 27435265
  7. Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 41478536
  8. Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis. animal study; mechanism-focused research / 1 linked research note PubMed 40580876
  9. Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40568800
  10. Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39596290
  11. The antinociceptive activity and mechanism of action of cannabigerol. animal study; preclinical research / 2 linked research notes PubMed 36916438
  12. Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. animal study; mechanism-focused research / 1 linked research note PubMed 40725084
  13. Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. evidence still limited / 1 linked research note PubMed 36768709
  14. In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. clinical study in people; mechanism-focused research / 1 linked research note PubMed 35056807
  15. Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. animal study; mechanism-focused research / 1 linked research note PubMed 39851511
  16. Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. human research / 1 linked research note PubMed 40124934
  17. Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37949940
  18. Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39647320
  19. Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. evidence still limited / 2 linked research notes PubMed 38889235
  20. The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37652708
  21. A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39357769
  22. Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents. cell or laboratory study; evidence still limited / 1 linked research note PubMed 41645347
  23. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 27094344
  24. Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 42163693
  25. The Potential of Cannabichromene (CBC) as a Therapeutic Agent. narrative or expert review; evidence still limited / 1 linked research note PubMed 38777605
  26. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37630401
  27. Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. animal study; preclinical research / 1 linked research note PubMed 40580638
  28. Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38885660
  29. Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. animal study; mechanism-focused research / 1 linked research note PubMed 39769302
  30. Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. narrative or expert review; evidence still limited / 1 linked research note PubMed 39457041
  31. Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus. narrative or expert review; evidence still limited / 1 linked research note PubMed 39596719
  32. Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 35628241
  33. Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties. animal study; mechanism-focused research / 1 linked research note PubMed 37242431
  34. Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36769042
  35. Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis. evidence still limited / 1 linked research note PubMed 35354487
  36. Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential. evidence still limited / 1 linked research note PubMed 41202683
  37. Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V. evidence still limited / 1 linked research note PubMed 41121423
  38. Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. human research / 1 linked research note PubMed 41983582
  39. Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37514074
  40. Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids. evidence still limited / 1 linked research note PubMed 38927152
  41. Biological activity of cannabichromene, its homologs and isomers. animal study; preclinical research / 1 linked research note PubMed 7298870